Breaking News Instant updates and real-time market news.

MRK

Merck

$63.89

0.89 (1.41%)

, INCY

Incyte

$128.80

8.31 (6.90%)

08:50
05/19/17
05/19
08:50
05/19/17
08:50

Merck leadership in NSCLC 'solidified,' says BMO Capital

BMO Capital analyst Alex Arfaei says that "the ASCO abstracts solidify Merck's (MRK) significant leadership in the important 1L-NSCLC market." The analyst says that Incyte's (INCY) Epacadostat appears to be "adding meaningful clinical benefit to Keytruda." He believes that the data "clearly indicates" that Keytruda monotherapy should be the standard of care in about 25% of 1L-NSCLC patients.

MRK

Merck

$63.89

0.89 (1.41%)

INCY

Incyte

$128.80

8.31 (6.90%)

  • 22

    May

  • 23

    May

  • 27

    May

  • 31

    May

  • 02

    Jun

  • 05

    Jun

  • 09

    Jun

  • 14

    Jun

MRK Merck
$63.89

0.89 (1.41%)

04/04/17
STFL
04/04/17
NO CHANGE
STFL
NewLink Genetics should be bought on weakness after data, says Stifel
Stifel analyst Stephen Willey said NewLink Genetics' (NLNK) combination of indoximod and Merck's (MRK) pembrolizumab in patients with treatment-naive melanoma demonstrated an overall response rate, or ORR, that is "essentially identical" to the previously-reported results from the Incyte (INCY)-Merck study of epacadostat/pembrolizumab. The lower rate of complete responses he doesn't "find terribly surprising" given what is already known about the current indoximod formulation, he tells investors. Willey, who views today's weakness as an interesting buying opportunity ahead of P1/2 data on the atezolizumab + GDC-0919 combination, keeps a Buy rating on Newlink shares.
04/20/17
JEFF
04/20/17
NO CHANGE
Target $51
JEFF
Underperform
Jefferies lowers Merck estimates, drops target to $51
Jefferies analyst Jeffrey Holford lowered his earnings estimates for Merck by up to 3% citing concerns on pricing for Januvia/Janumet. The analyst notes that his mid-term estimates are now up to 11% below consensus. Holford expects Keytruda, Januvia and Gardasil to miss expectations Q1. He cut his price target for Merck to $51 from $52 and keeps an Underperform rating on the name.
05/03/17
BMOC
05/03/17
NO CHANGE
BMOC
Merck results more positive than first appeared, says BMO Capital
BMO Capital analyst Alex Arfaei says he's more upbeat on Merck's Q1 results following its conference call. He says that the lower than expected Januvia revenue is "explainable," while the company's Keytruda drug looks set to beat expectations in 2H17. The analyst expects the company's 2017 results to come in at the top half of its guidance range, and he thinks the stock can rise, driven by Keytruda and its hepatitis C treatments. The analyst keeps an Outperform rating on the shares.
05/11/17
BMOC
05/11/17
NO CHANGE
BMOC
Merck Keytruda approval positive, says BMO Capital
BMO Capital analyst Alex Arfaei notes that the FDA approved Keytruda + chemo in first line NSCLC. The analyst says that the label is "solid," and he expects "strong uptake" for the drug in the condition, based on his checks with oncologists. The analyst raised his price target on the shares to $74 from $71 and keeps an Outperform rating on the stock.
INCY Incyte
$128.80

8.31 (6.90%)

05/09/17
FBCO
05/09/17
NO CHANGE
Target $152
FBCO
Outperform
Incyte price target lowered to $152 from $167 at Credit Suisse
Credit Suisse analyst Alethia Young lowered her price target for Incyte to $152 from $167 due to moving from M&A base case valuation. While the analyst says it is possible that one day Incyte is bought, she thinks the company is progressing well in diversifying its pipeline base and de-risking its IDO inhibitor epacadostat. Young reiterates an Outperform rating on the shares.
05/11/17
OPCO
05/11/17
INITIATION
Target $125
OPCO
Perform
Incyte initiated with a Perform at Oppenheimer
Oppenheimer analyst Jay Olson initiated Incyte with a Perform and a $125 price target to reflect the valuation premium driven by takeover speculation. The analyst has no insight into the speculation but also said expectations are high going into ASCO for Incyte's epacadostat to deliver impressive benefits in combo with Keytrude in lung cancer.
05/18/17
JPMS
05/18/17
NO CHANGE
Target $149
JPMS
Overweight
Incyte data to 'restore positive sentiment,' says JPMorgan
JPMorgan analyst Cory Kasimov believes last night's abstracts for epacadostat demonstrate "consistent and compelling evidence" of efficacy across multiple tumor types, consistent with what Incyte has been telling with Street. The analyst is "encouraged" by emerging data and expect it will "restore positive sentiment" in the name and add to the company's perceived strategic value. He reiterates an Overweight rating on Incyte shares with a $149 price target.
05/18/17
BMOC
05/18/17
NO CHANGE
BMOC
Incyte price target raised to $155 from $146 at BMO Capital
BMO Capital analyst M. Ian Somaiya raised his price target on Incyte as he increased the chances of success of the company's epacadostat + PD-1 combination in four solid tumors following favorable data. The analyst adds that the combination's position was also helped by "lackluster" data on NewLink's (NLNK) IDO, drug, GDC-0919. He raised his price target on Incyte to $155 from $146.

TODAY'S FREE FLY STORIES

VBTX

Veritex

$26.94

-0.17 (-0.63%)

19:29
10/23/17
10/23
19:29
10/23/17
19:29
Earnings
Veritex reports Q3 core EPS 28c, consensus 30c »

For the three months…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

OIBR

Oi S.A.

19:08
10/23/17
10/23
19:08
10/23/17
19:08
Hot Stocks
Oi: Court postpones general meeting of creditors »

Oi announced that, at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAS

Hasbro

$89.75

-8.44 (-8.60%)

18:24
10/23/17
10/23
18:24
10/23/17
18:24
Hot Stocks
Hasbro CEO: Had a very strong quarter »

Expects to make a revised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

LGF.A

Lionsgate

$29.59

-0.5 (-1.66%)

, LGF.B

Lionsgate

$28.44

-0.6 (-2.07%)

18:07
10/23/17
10/23
18:07
10/23/17
18:07
Hot Stocks
Lionsgate names Rohit Jain to head new office in Mumbai, India »

Lionsgate (LGF.A, LGF.B)…

LGF.A

Lionsgate

$29.59

-0.5 (-1.66%)

LGF.B

Lionsgate

$28.44

-0.6 (-2.07%)

DISH

Dish

$48.98

-0.32 (-0.65%)

VDTH

Videocon d2h

$8.00

-0.22 (-2.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

  • 09

    Nov

ALE

Allete

$78.62

-0.31 (-0.39%)

18:06
10/23/17
10/23
18:06
10/23/17
18:06
Hot Stocks
Wisconsin jury delivers verdict in favor of U.S. Water in Novozymes suit »

U.S. Water, an Allete…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 05

    Nov

SYT

Syngenta

$92.12

0.05 (0.05%)

, ADAM

A.D.A.M.

18:04
10/23/17
10/23
18:04
10/23/17
18:04
Hot Stocks
Syngenta and Adama to sell portfolio of crop products to Nufarm for $490M »

Syngenta (SYT) announced…

SYT

Syngenta

$92.12

0.05 (0.05%)

ADAM

A.D.A.M.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$98.70

-0.7 (-0.70%)

17:54
10/23/17
10/23
17:54
10/23/17
17:54
Periodicals
Disney sees new 'Thor' movie outpacing earlier ones, Bloomberg says »

Disney sees "Thor:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

VIVO

Meridian Bioscience

$15.20

-0.6 (-3.80%)

17:31
10/23/17
10/23
17:31
10/23/17
17:31
Hot Stocks
Meridian Bioscience comments on FDA Warning Letter issued to subsidiary »

Meridian Bioscience…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APRN

Blue Apron

$5.15

0.07 (1.38%)

17:30
10/23/17
10/23
17:30
10/23/17
17:30
Hot Stocks
Blue Apron names Lainie Cooney chief HR officer »

Blue Apron announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

WSFS

WSFS Financial

$50.25

-0.5 (-0.99%)

17:29
10/23/17
10/23
17:29
10/23/17
17:29
Hot Stocks
WSFS Financial raises quarterly dividend 29% to 9c per share »

The dividend will be paid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 06

    Nov

  • 15

    Nov

CONN

Conn's

$26.85

-0.75 (-2.72%)

17:28
10/23/17
10/23
17:28
10/23/17
17:28
Hot Stocks
Conn's sees Q3 SSS down 9% to down 5%, provision for bad debts at $56M-$61M »

The company states:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WSFS

WSFS Financial

$50.25

-0.5 (-0.99%)

17:27
10/23/17
10/23
17:27
10/23/17
17:27
Earnings
WSFS Financial reports Q3 EPS 64c, consensus 65c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 06

    Nov

  • 15

    Nov

VBTX

Veritex

$26.94

-0.17 (-0.63%)

17:27
10/23/17
10/23
17:27
10/23/17
17:27
Hot Stocks
Veritex names Michael Bryan chief information officer »

Veritex Holdings, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

TNDM

TNDM

17:25
10/23/17
10/23
17:25
10/23/17
17:25
Hot Stocks
Breaking Hot Stocks news story on TNDM »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

CLB

Core Laboratories

$87.75

-1.74 (-1.94%)

17:21
10/23/17
10/23
17:21
10/23/17
17:21
Hot Stocks
Core Laboratories sees Q4 free cash flow exceeding net income »

Fourth quarter 2017 FCF…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

CLB

Core Laboratories

$87.75

-1.74 (-1.94%)

17:20
10/23/17
10/23
17:20
10/23/17
17:20
Earnings
Core Laboratories sees Q4 revenue approximately 58c, consensus 58c »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

CLB

Core Laboratories

$87.75

-1.74 (-1.94%)

17:18
10/23/17
10/23
17:18
10/23/17
17:18
Earnings
Core Laboratories reports Q3 GAAP EPS 48c, consensus 44c »

Reports Q3 revenue $166M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

LKQ

LKQ Corp.

$37.06

-0.28 (-0.75%)

, DOV

Dover

$95.54

0.59 (0.62%)

17:17
10/23/17
10/23
17:17
10/23/17
17:17
Hot Stocks
LKQ Corp to acquire aftermarket business of Dover subsidiary Warn Industries »

LKQ Corporation (LKQ)…

LKQ

LKQ Corp.

$37.06

-0.28 (-0.75%)

DOV

Dover

$95.54

0.59 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

KNL

Knoll

$20.00

-0.02 (-0.10%)

, HMST

HomeStreet

$28.60

-0.25 (-0.87%)

17:17
10/23/17
10/23
17:17
10/23/17
17:17
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Knoll…

KNL

Knoll

$20.00

-0.02 (-0.10%)

HMST

HomeStreet

$28.60

-0.25 (-0.87%)

CR

Crane

$83.61

-0.5 (-0.59%)

IPXL

Impax

$20.35

-0.9 (-4.24%)

ICPT

Intercept

$65.60

-1.25 (-1.87%)

SWK

Stanley Black & Decker

$158.19

-1.93 (-1.21%)

NKE

Nike

$53.66

0.6 (1.13%)

HNI

HNI Corporation

$42.29

-0.57 (-1.33%)

WHR

Whirlpool

$182.50

0.04 (0.02%)

ZION

Zions Bancorp

$46.39

-0.37 (-0.79%)

JBT

John Bean Technologies

$104.05

0.1 (0.10%)

IMDZ

Immune Design

CRBP

Corbus Pharmaceuticals

$7.40

-0.375 (-4.82%)

QURE

uniQure

$18.52

-0.75 (-3.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 06

    Nov

  • 08

    Nov

  • 09

    Nov

  • 09

    Nov

  • 13

    Nov

  • 14

    Nov

  • 14

    Nov

  • 15

    Nov

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

HBI

Hanesbrands

$22.86

-0.63 (-2.68%)

17:17
10/23/17
10/23
17:17
10/23/17
17:17
Initiation
Hanesbrands initiated at Deutsche Bank »

Hanesbrands initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

PVH

PVH Corp.

$129.68

1.37 (1.07%)

17:15
10/23/17
10/23
17:15
10/23/17
17:15
Initiation
PVH Corp. initiated at Deutsche Bank »

PVH Corp. initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NYT

New York Times

$19.55

0.1 (0.51%)

17:15
10/23/17
10/23
17:15
10/23/17
17:15
Hot Stocks
Breaking Hot Stocks news story on New York Times »

Darsana Capital Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$1.01

0.01 (1.00%)

17:07
10/23/17
10/23
17:07
10/23/17
17:07
Hot Stocks
U.S. Energy announces participation in upcoming drilling program »

U.S. Energy announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KOS

Kosmos

$7.44

-0.07 (-0.93%)

, HES

Hess Corp.

$45.21

0.18 (0.40%)

17:05
10/23/17
10/23
17:05
10/23/17
17:05
Hot Stocks
Kosmos to acquire interest in exploration licenses in Gulf of Guinea for $650M »

Kosmos Energy announced…

KOS

Kosmos

$7.44

-0.07 (-0.93%)

HES

Hess Corp.

$45.21

0.18 (0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 06

    Nov

FULT

Fulton Financial

17:04
10/23/17
10/23
17:04
10/23/17
17:04
Hot Stocks
Fulton Financial: Mark McCollom to assume CFO role in early 2018 »

Fulton Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 02

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.